Abstract:The clinical utility of the carbonic anhydrase (CA) inhibitor acetazolamide (ACTZ) is limited because of rapid development of tolerance to its effects. Tolerance is thought to develop as a result of glial cell proliferation and/or increased CA synthesis. DBA mice, susceptible to audiogenic seizures (AGSs) in an age-dependent manner, have increased CA activity as compared with C57 (non-audiogenic seizure susceptible) mice at 21 and 110 days of age. The present work utilized ACTZ to help determine the relationsh… Show more
“…D2 mice are exquisitely sensitive to soundinduced (audiogenic) seizures until the age of -3 weeks (Hall, 1947). Although D2 mice acquire resistance to audiogenic seizures with maturity, previous work has shown that they remain hyperexcit-able to electrical stimulation throughout adult life (Engstrom et al, 1986). Results of our study confirm that mature D2 mice are more vulnerable than mature B6 mice to induction of behavioral seizures after systemic injection of KA.…”
Mature DBA/2J (D2) and C57BL/6J (B6) mice aged 9-10 weeks were studied to determine susceptibility to behavioral seizures induced by kainic acid (KA) and the possible influence exerted by differences in metabolism and blood-brain barrier (BBB) transport. Mice were observed for 4 h after subcutaneous (s.c.) KA injection. Behavioral seizure parameters included latency to first seizure (clonus), latency to tonic/clonic seizure, and latency to status epilepticus (SE). At a KA dose of 25 mg/kg, 80% of D2 mice exhibited tonic/clonic seizures, whereas all B6 mice remained seizure-free. At 30 mg/kg, tonic/clonic seizures were observed in 100% of D2 mice and 25% of B6 mice. Of D2 mice exhibiting at least one clonic seizure in response to KA at a dose of 25 mg/kg, 50% entered SE and eventually died. Administration of [3H]KA (6.6 x 10(6) dpm) at doses of 25 mg/kg (convulsive) or 11.1 micrograms (nonconvulsive) to mice of both strains resulted in similar levels of radioactivity in cortex, hippocampus, and cerebellum 30 and 60 min after injection. Bioconversion of [3H]KA to a radiolabeled brain metabolite in vivo could not be documented in mice from either strain. Results confirm previously reported differences between D2 and B6 mice in their relative susceptibility to seizures induced by systemic KA administration and suggest that these differences are not related to strain-specific variation in metabolism or BBB transport of KA. Further studies of these two strains of mice may be useful for investigating genetic influences upon seizure susceptibility.
“…D2 mice are exquisitely sensitive to soundinduced (audiogenic) seizures until the age of -3 weeks (Hall, 1947). Although D2 mice acquire resistance to audiogenic seizures with maturity, previous work has shown that they remain hyperexcit-able to electrical stimulation throughout adult life (Engstrom et al, 1986). Results of our study confirm that mature D2 mice are more vulnerable than mature B6 mice to induction of behavioral seizures after systemic injection of KA.…”
Mature DBA/2J (D2) and C57BL/6J (B6) mice aged 9-10 weeks were studied to determine susceptibility to behavioral seizures induced by kainic acid (KA) and the possible influence exerted by differences in metabolism and blood-brain barrier (BBB) transport. Mice were observed for 4 h after subcutaneous (s.c.) KA injection. Behavioral seizure parameters included latency to first seizure (clonus), latency to tonic/clonic seizure, and latency to status epilepticus (SE). At a KA dose of 25 mg/kg, 80% of D2 mice exhibited tonic/clonic seizures, whereas all B6 mice remained seizure-free. At 30 mg/kg, tonic/clonic seizures were observed in 100% of D2 mice and 25% of B6 mice. Of D2 mice exhibiting at least one clonic seizure in response to KA at a dose of 25 mg/kg, 50% entered SE and eventually died. Administration of [3H]KA (6.6 x 10(6) dpm) at doses of 25 mg/kg (convulsive) or 11.1 micrograms (nonconvulsive) to mice of both strains resulted in similar levels of radioactivity in cortex, hippocampus, and cerebellum 30 and 60 min after injection. Bioconversion of [3H]KA to a radiolabeled brain metabolite in vivo could not be documented in mice from either strain. Results confirm previously reported differences between D2 and B6 mice in their relative susceptibility to seizures induced by systemic KA administration and suggest that these differences are not related to strain-specific variation in metabolism or BBB transport of KA. Further studies of these two strains of mice may be useful for investigating genetic influences upon seizure susceptibility.
“…In CS7 mice, the maximum amount of enzyme per cell at each dose was obtained 24 h after beginning treatment and no further increases were observed with time (Fig. Nevertheless, the persistent increases in CA in DBA mice may explain why they do not become tolerant to the protective effects of acetazolamide on MES (Engstrom et al, 1986). In contrast, the amount of enzymes per cell in DBA mice continued to increase with time and dose up to S days after beginning acetazolamide treatment (Fig.…”
Section: Discussionmentioning
confidence: 88%
“…Tolerance to protection from MES develops in C57, but not in DBA mice (Engstrom et al, 1986). The elevated quantity of CA in DBA mice, thus, may represent the effects of a functional inhibition of the enzyme.…”
Section: Discussionmentioning
confidence: 93%
“…DBA mice have a lower electroshock seizure threshold than C57 mice, but protection from MES is achieved with a fourfold higher dose of acetazolamide in DBA than in C57 mice (Engstrom et a!., 1986). Cerebral cortex sections of DBA/2J (audiogenic seizures-susceptible) mice and C57BL/6J (related, nonsusceptible strain) mice were stained with antibody to mouse CA I1 (high-activity isoenzyme) in controls and following treatment with acetazolamide for 1, 3, and 5 days.…”
mentioning
confidence: 99%
“…The fluorescent intensity of single cells in the cortex was measured with a fluorescent intensity detector in a fluorescent microscope. DBA mice have a lower electroshock seizure threshold than C57 mice, but protection from MES is achieved with a fourfold higher dose of acetazolamide in DBA than in C57 mice (Engstrom et a!., 1986). Furthermore, tolerance to acetazolamide suppression of MES develops in C57 mice, but not in DBA mice (Engstrom et al, 1986).…”
The mechanism by which animals develop tolerance to the antiepileptic effects of the carbonic anhydrase (CA) inhibitor, acetazolamide, was explored using a quantitative immunocytochemical method. Cerebral cortex sections of DBA/2J mice susceptible to audiogenic seizures and of C57BL/6J nonsusceptible mice were stained with antibody to mouse CA II in controls and following treatment with acetazolamide (40 and 200 mg/kg) for 1, 3, and 5 days. The percentage increases in CA II fluorescent intensity of cells from C57 mice treated with 40 and 200 mg/kg acetazolamide over those of untreated mice were 22 and 36%, respectively, after 1 day, 32 and 40%, respectively, after 3 days, and 17 and 40%, respectively, after 5 days of treatment. The corresponding percentage increases in fluorescent intensity of cells from DBA mice over controls were 13 and 32%, respectively, after 1 day, 17 and 41%, respectively, after 3 days, and 26 and 58%, respectively, after 5 days of treatment. The fluorescent intensity of cells from untreated DBA mice was 35% greater than those of untreated C57 mice. In C57 mice the maximum amount of CA II per cell at each dose occurred 24 h after acetazolamide treatment, whereas the amount in DBA mice continued to increase with time and dose up to 5 days. The differences between the two strains can be explained by changes in distribution of CA II to subcellular locations or by defects in phosphorylation of the molecule.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.